Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 48,35€(+16,23%). Der Median liegt bei 48,35€(+16,23%).
Kaufen | 11 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.» Mehr auf marketbeat.com
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to the Russell 2000 ® and Russell 3000 ® Indexes.» Mehr auf globenewswire.com
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per share. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering expenses, were $402.5 million. All of the shares in the offering were sold by Cidara.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | 100,00% |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −21,70 Mio | 126,84% |
EBITDA | −23,31 Mio | 144,98% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 535,84 Mio€ |
Anzahl Aktien | 12,97 Mio |
52 Wochen-Hoch/Tief | 48,20€ - 8,60€ |
Dividenden | Nein |
Beta | 0,8 |
KGV (PE Ratio) | −3,82 |
KGWV (PEG Ratio) | −1,83 |
KBV (PB Ratio) | 4,87 |
KUV (PS Ratio) | 2.091,92 |
Unternehmensprofil
Name | Cidara Therapeutics Aktie |
CEO | Jeffrey L. Stein |
Sitz | San Diego, ca USA |
Industrie | Biotechnologie |
Mitarbeiter | 38 |
Assets entdecken
Shareholder von Cidara Therapeutics Aktie investieren auch in folgende Assets